PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22802261-4 2012 We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance. Epirubicin 99-109 mitogen-activated protein kinase 14 Homo sapiens 23-26 31537377-5 2019 Epirubicin induces activation of p38-MK2 signaling pathway to phosphorylate gp130 at Ser 782, which results in gp130 internalization and degradation by lysosome. Epirubicin 0-10 mitogen-activated protein kinase 14 Homo sapiens 33-36 29541177-4 2018 The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK. Epirubicin 151-161 mitogen-activated protein kinase 14 Homo sapiens 217-220 29541177-4 2018 The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK. Epirubicin 151-161 mitogen-activated protein kinase 14 Homo sapiens 265-268 29541177-4 2018 The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK. Epirubicin 151-161 mitogen-activated protein kinase 14 Homo sapiens 265-268 28423359-4 2017 Mechanically, the chemotherapeutic drug epidoxorubicin induces GRO-alpha expression in primary bladder cancer cells at G1/S phase via p38-dependent activation of NF-kappaB. Epirubicin 40-54 mitogen-activated protein kinase 14 Homo sapiens 134-137 25759054-10 2015 Moreover, exposure to epirubicin increased intracellular lipid peroxide levels and enhanced the phosphorylation of p38 mitogen-activated protein kinase. Epirubicin 22-32 mitogen-activated protein kinase 14 Homo sapiens 115-118 22802261-0 2012 The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment. Epirubicin 64-74 mitogen-activated protein kinase 14 Homo sapiens 4-7 27272157-9 2016 In conclusion, Paeonol (a) enhanced the antitumor activity of Epirubicin in a synergistic manner against breast cancer cells via inhibiting p38/JNK/ERK MAPKs and (b) alleviated Epirubicin-induced cardiotoxicity by suppressing NF-kB pathway. Epirubicin 62-72 mitogen-activated protein kinase 14 Homo sapiens 140-143 22802261-4 2012 We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance. Epirubicin 99-109 mitogen-activated protein kinase 14 Homo sapiens 178-181 22802261-4 2012 We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance. Epirubicin 227-237 mitogen-activated protein kinase 14 Homo sapiens 23-26 22802261-4 2012 We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance. Epirubicin 227-237 mitogen-activated protein kinase 14 Homo sapiens 178-181 22802261-8 2012 In addition, the p38-MK2 axis can also limit c-jun-NH(2)-kinase (JNK) induction by epirubicin and, notably, JNK represses FOXM1 expression. Epirubicin 83-93 mitogen-activated protein kinase 14 Homo sapiens 17-20 22330067-0 2012 Activation of p38 MAPK by oxidative stress underlying epirubicin-induced vascular endothelial cell injury. Epirubicin 54-64 mitogen-activated protein kinase 14 Homo sapiens 14-17 22330067-8 2012 The epirubicin-induced cell injury and increase of caspase-3/7 activity were also attenuated by p38 mitogen-activated protein kinase (MAPK) inhibitors, SB203580 and PD169316. Epirubicin 4-14 mitogen-activated protein kinase 14 Homo sapiens 96-99 22330067-9 2012 Moreover, epirubicin significantly enhanced the phosphorylation of p38 MAPK, and these effects were attenuated by GSH and NAC. Epirubicin 10-20 mitogen-activated protein kinase 14 Homo sapiens 67-70 22330067-11 2012 These results indicate that an activation of p38 MAPK by oxidative stress is involved in the epirubicin-induced endothelial cell injury. Epirubicin 93-103 mitogen-activated protein kinase 14 Homo sapiens 45-48 19781349-0 2009 [Study of the relationship between early growth response gene 1 activity in p38 mitogen-activated protein kinase pathway and epirubicin resistance of human breast carcinoma cells]. Epirubicin 125-135 mitogen-activated protein kinase 14 Homo sapiens 76-79 19781349-1 2009 OBJECTIVE: To investigate the relationship between activities of early growth response gene 1 (EGR-1) of p38 mitogen-activated protein kinase (MAPK) pathway and in the epirubicin resistance of breast carcinoma cells. Epirubicin 168-178 mitogen-activated protein kinase 14 Homo sapiens 105-108